DK1356046T3 - Cytokinreceptor zcytoR19 - Google Patents

Cytokinreceptor zcytoR19

Info

Publication number: DK1356046T3
Authority: DK; Denmark
Prior art keywords: polypeptides; zcytor19; methods; cytokine receptor; vitro
Prior art date: 2000-11-28

Application number

DK01988203.4T

Other languages

English (en)

Inventor

Theodore E Whitmore

Francis J Grant

Scott R Presnell

Wenfeng Xu

Julia E Novak

Original Assignee

Zymogenetics L L C

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-28

Filing date

2001-11-28

Publication date

2010-03-01

2001-11-28 Application filed by Zymogenetics L L C, Bristol Myers Squibb Co filed Critical Zymogenetics L L C

2010-03-01 Application granted granted Critical

2010-03-01 Publication of DK1356046T3 publication Critical patent/DK1356046T3/da

Links

102000003675 cytokine receptors Human genes 0.000 title abstract 2
108010057085 cytokine receptors Proteins 0.000 title abstract 2
229920001184 polypeptide Polymers 0.000 abstract 4
102000004196 processed proteins & peptides Human genes 0.000 abstract 4
108090000765 processed proteins & peptides Proteins 0.000 abstract 4
239000003446 ligand Substances 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
238000000338 in vitro Methods 0.000 abstract 2
238000001727 in vivo Methods 0.000 abstract 2
102000040430 polynucleotide Human genes 0.000 abstract 2
108091033319 polynucleotide Proteins 0.000 abstract 2
239000002157 polynucleotide Substances 0.000 abstract 2
210000000349 chromosome Anatomy 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000003394 haemopoietic effect Effects 0.000 abstract 1
210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
210000004698 lymphocyte Anatomy 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
210000000066 myeloid cell Anatomy 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Cell Biology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)

DK01988203.4T 2000-11-28 2001-11-28 Cytokinreceptor zcytoR19 DK1356046T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25356100P	2000-11-28	2000-11-28
US26721101P	2001-02-07	2001-02-07
PCT/US2001/044808 WO2002044209A2 (en)	2000-11-28	2001-11-28	Cytonkine receptor zcytor19

Publications (1)

Publication Number	Publication Date
DK1356046T3 true DK1356046T3 (da)	2010-03-01

Family

ID=26943370

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01988203.4T DK1356046T3 (da)	2000-11-28	2001-11-28	Cytokinreceptor zcytoR19

Country Status (12)

Country	Link
US (10)	US20030027253A1 (da)
EP (1)	EP1356046B1 (da)
JP (1)	JP2004532611A (da)
AT (1)	ATE445701T1 (da)
AU (1)	AU2002241533A1 (da)
CA (1)	CA2430485A1 (da)
CY (1)	CY1110921T1 (da)
DE (1)	DE60140213D1 (da)
DK (1)	DK1356046T3 (da)
ES (1)	ES2334888T3 (da)
PT (1)	PT1356046E (da)
WO (1)	WO2002044209A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1356046T3 (da)	2000-11-28	2010-03-01	Zymogenetics L L C	Cytokinreceptor zcytoR19
TW200300170A (en) *	2001-11-09	2003-05-16	Wyeth Corp	Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) *	2001-12-21	2006-04-25	Ludwig Institute For Cancer Research	Isolated cytokine receptor LICR-2
EP1497415B1 (en) *	2002-04-19	2010-12-29	ZymoGenetics, L.L.C.	Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
US20040170982A1 (en) *	2003-02-14	2004-09-02	Morris David W.	Novel therapeutic targets in cancer
US20060246161A1 (en) *	2003-02-21	2006-11-02	Hongtao Xing	Method of making medicament for treating anemia
PT2251353E (pt)	2003-08-07	2013-05-07	Zymogenetics Inc	Preparações homogéneas de il-28 e il-29
ATE517914T1 (de)	2004-03-08	2011-08-15	Zymogenetics Inc	Dimere fusionsproteine und materialien und verfahren zu deren herstellung
WO2006012644A2 (en)	2004-07-29	2006-02-02	Zymogenetics, Inc.	Use of il-28 and il-29 to treat cancer
AU2006272978B2 (en)	2005-07-26	2012-06-07	Bial - Portela & Ca, S.A.	Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en)	2006-04-10	2007-10-17	Portela & Ca., S.A.	Oxadiazole derivatives as COMT inhibitors
CN101631548B (zh)	2007-01-31	2014-08-27	比艾尔-坡特拉有限公司	Comt抑制剂的单次药物剂量单元和药物组合物
JP2011502163A (ja) *	2007-10-31	2011-01-20	ザスクリプスリサーチインスティテュート	持続性ウイルス感染を治療するための併用療法
JP5864410B2 (ja) *	2009-04-01	2016-02-17	ノヴィファーマソシエテアノニム	ニトロカテコール誘導体を含む医薬製剤及びその製造方法
KR102023255B1 (ko) *	2009-04-01	2019-09-19	바이알 - 포르텔라 앤드 씨에이 에스에이	니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
US20140045900A1 (en)	2011-02-11	2014-02-13	Bial-Portela & Ca, S.A.	Administration regime for nitrocatechols
MX2013014773A (es) *	2011-06-13	2014-01-20	Merck Sharp & Dohme	Procedimiento de purificacion de formas nativas o mutantes de la toxina difterica.
BR112014014341A2 (pt)	2011-12-13	2017-08-22	Bial Portela & Ca Sa	Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
MX2015012562A (es) *	2013-03-15	2016-06-21	Abbvie Inc	Purificacion de conjugados anticuerpo-farmaco (cafs).
TW201446961A (zh) *	2013-05-06	2014-12-16	Abbvie Inc	用於細胞培養之組合物及其使用方法
WO2016033509A1 (en) *	2014-08-29	2016-03-03	The Regents Of The University Of Colorado, A Body Corporate	Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica
WO2016083863A1 (en)	2014-11-28	2016-06-02	Bial - Portela & Ca, S.A.	Medicaments for slowing parkinson's disease
WO2017180713A1 (en) *	2016-04-13	2017-10-19	Orimabs Ltd.	Anti-psma antibodies and use thereof
US20250129132A1 (en) *	2021-09-21	2025-04-24	University Of Washington	Genetically encoded and exogenously triggered protein-protein ligation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7625697B2 (en) *	1994-06-17	2009-12-01	The Board Of Trustees Of The Leland Stanford Junior University	Methods for constructing subarrays and subarrays made thereby
US5945511A (en) *	1997-02-20	1999-08-31	Zymogenetics, Inc.	Class II cytokine receptor
US5965704A (en) *	1997-08-05	1999-10-12	Zymogenetics, Inc.	Class two cytokine receptor-11
JP2003518920A (ja)	1999-07-02	2003-06-17	カイロンコーポレイション	新規なヒト遺伝子および遺伝子発現産物
EP2298789B1 (en) *	2000-09-08	2012-03-14	Schering Corporation	Mammalian genes; related reagents and methods
DK1356046T3 (da) *	2000-11-28	2010-03-01	Zymogenetics L L C	Cytokinreceptor zcytoR19
BR0205083A (pt) *	2001-04-20	2004-07-20	Zymogenetics Inc	Polipeptìdeo isolado, composição farmacêutica, proteìna de fusão, polinucleotìdeo isolado, vetor de expressão, célula hospedeira recombinante e métodos de produzir um polipeptìdeo, de detectar a presença da expressão de gene em uma amostra biológica, de expandir células monocìticas ou progenitores de células de monócitos e de estimular uma resposta imune em um mamìfero exposto a um antìgeno ou patógeno
EP1439223A1 (en)	2001-10-02	2004-07-21	Mochida Pharmaceutical Co., Ltd.	Novel class ii cytokine receptor
TW200300170A (en) *	2001-11-09	2003-05-16	Wyeth Corp	Type 2 cytokine receptor and nucleic acids encoding same
US7033787B2 (en) *	2001-12-21	2006-04-25	Ludwig Institute For Cancer Research	Isolated cytokine receptor LICR-2
WO2003066002A2 (en)	2002-02-08	2003-08-14	University Of Medicine And Dentistry Of New Jersey	IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
EP1497415B1 (en)	2002-04-19	2010-12-29	ZymoGenetics, L.L.C.	Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
JP2006509041A (ja)	2002-10-23	2006-03-16	ザイモジェネティクス，インコーポレイティド	Ｉｌ−２８およびｉｌ−２９を用いるウイルス感染を治療するための方法
CA2516128A1 (en)	2003-02-14	2004-09-02	Sagres Discovery, Inc.	Therapeutic targets in cancer

2001
- 2001-11-28 DK DK01988203.4T patent/DK1356046T3/da active
- 2001-11-28 CA CA002430485A patent/CA2430485A1/en not_active Abandoned
- 2001-11-28 DE DE60140213T patent/DE60140213D1/de not_active Expired - Lifetime
- 2001-11-28 ES ES01988203T patent/ES2334888T3/es not_active Expired - Lifetime
- 2001-11-28 AT AT01988203T patent/ATE445701T1/de active
- 2001-11-28 WO PCT/US2001/044808 patent/WO2002044209A2/en not_active Ceased
- 2001-11-28 AU AU2002241533A patent/AU2002241533A1/en not_active Abandoned
- 2001-11-28 US US09/995,898 patent/US20030027253A1/en not_active Abandoned
- 2001-11-28 PT PT01988203T patent/PT1356046E/pt unknown
- 2001-11-28 EP EP01988203A patent/EP1356046B1/en not_active Expired - Lifetime
- 2001-11-28 JP JP2002546578A patent/JP2004532611A/ja active Pending
2005
- 2005-06-23 US US11/165,141 patent/US20050266485A1/en not_active Abandoned
2006
- 2006-10-05 US US11/539,064 patent/US7608452B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/539,072 patent/US7601809B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/539,079 patent/US20070048846A1/en not_active Abandoned
- 2006-10-06 US US11/539,286 patent/US7618791B2/en not_active Expired - Lifetime
- 2006-10-06 US US11/539,283 patent/US20070048804A1/en not_active Abandoned
2010
- 2010-01-14 CY CY20101100038T patent/CY1110921T1/el unknown
- 2010-04-08 US US12/756,985 patent/US20110091876A1/en not_active Abandoned
2011
- 2011-10-06 US US13/267,430 patent/US20120064571A1/en not_active Abandoned
2014
- 2014-04-02 US US14/243,708 patent/US20140248661A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2334888T3 (es)	2010-03-17
EP1356046B1 (en)	2009-10-14
US20070048799A1 (en)	2007-03-01
WO2002044209A2 (en)	2002-06-06
US20050266485A1 (en)	2005-12-01
WO2002044209A3 (en)	2003-08-21
US20070048846A1 (en)	2007-03-01
US20070111942A1 (en)	2007-05-17
CY1110921T1 (el)	2015-06-10
JP2004532611A (ja)	2004-10-28
EP1356046A2 (en)	2003-10-29
US20030027253A1 (en)	2003-02-06
CA2430485A1 (en)	2002-06-06
US20070048804A1 (en)	2007-03-01
US20120064571A1 (en)	2012-03-15
ATE445701T1 (de)	2009-10-15
US7618791B2 (en)	2009-11-17
AU2002241533A1 (en)	2002-06-11
DE60140213D1 (de)	2009-11-26
US20110091876A1 (en)	2011-04-21
US20070117165A1 (en)	2007-05-24
US7601809B2 (en)	2009-10-13
US20140248661A1 (en)	2014-09-04
US7608452B2 (en)	2009-10-27
PT1356046E (pt)	2010-03-09

Publication	Publication Date	Title
DE60140213D1 (de)	2009-11-26	Zytokine rezeptor zcytor19
WO2002000721A3 (en)	2003-04-17	Cytokine receptor zcytor17
ATE349522T1 (de)	2007-01-15	Löslicher zytokinrezeptor zalpha11
NZ510744A (en)	2003-02-28	Cytokine receptor zalpha11
UA84387C2 (ru)	2008-10-27	Человеческий цитокин как лиганд зальфа рецептора и его применение
Kao et al.	1994	A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response
WO2002012345A3 (en)	2003-06-12	Soluble zcytor 11 cytokine receptors
DE69738066D1 (de)	2007-10-11	Hematopoietischer zytokin rezeptor
IL163067A (en)	2013-07-31	Isolated heterodimeric cytokine receptor
ATE273384T1 (de)	2004-08-15	Tie-2 liganden, herstellungsverfahren und verwendung
DE69837996D1 (de)	2007-08-09	Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
HUT77491A (hu)	1998-05-28	TIE-2 ligandumok, eljárás előállításukra és felhasználásuk
ATE368682T1 (de)	2007-08-15	Als 2f1 bezeichnetes rezeptorprotein
ATE294236T1 (de)	2005-05-15	Promotor der tie rezeptor protein kinase
MXPA02008239A (es)	2004-08-12	Gen humano de la esquizofrenia.
WO2003089603A3 (en)	2004-09-16	Cytokine receptor
MXPA03000227A (es)	2004-05-21	Compuestos novedosos.
PT877803E (pt)	2005-11-30	Receptor da proteina ob e composicoes e metodos afins
DK1021534T3 (da)	2010-02-01	Hepatitis C-receptorprotein CD81
NO993653D0 (no)	1999-07-27	Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
ATE232901T1 (de)	2003-03-15	Biologisch aktive ligande der eph familie
ATE319739T1 (de)	2006-03-15	Menschliche wingless-änhliche gene
Motozawa et al.	2018	Functional comparison of high and low molecular weight basic fibroblast growth factors
EP1736545A3 (en)	2007-03-28	Soluble zcytor 11 cytokine receptors
Paukovits	1991	Growth regulation and carcinogenesis